Mentice

Mentice Equity Ratio

The Equity Ratio of Mentice (MNTC.ST) as of Nov 19, 2026 is 44.35 %. In the previous year, Equity Ratio was 44.35 % — a change of -0.01% (lower).

Equity Ratio

44.35 %

YoY

-0.01%

Last updated:

Equity Ratio of Mentice is 2025 44.35 % . Equity Ratio of Mentice was 2024 44.35 % . It decreases by -0.01% lower compared to the previous year.

The Mentice Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
51.11 SEK
Jan 1, 2019
66.67 SEK
Jan 1, 2020
66.56 SEK
Jan 1, 2021
52.27 SEK
Jan 1, 2022
48.84 SEK
Jan 1, 2023
49.29 SEK
Jan 1, 2024
44.35 SEK
Jan 1, 2025
44.35 SEK
The Mentice Equity Ratio history
YEAREquity RatioYoY
44.35 %-0.01%
44.35 %-10.01%
49.29 %+0.92%
48.84 %-6.55%
52.27 %-21.47%
66.56 %-0.16%
66.67 %+30.45%
51.11 %-1.42%
51.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mentice Stock analysis

What does Mentice do? Mentice AB provides software and hardware simulation solutions for endovascular therapies, targeting healthcare professionals and the medical device industry. The company's solutions are scientifically validated and designed to help users acquire, retain, and enhance procedural skills in neurovascular, cardiovascular, and peripheral interventions. Mentice AB generates revenue through the sale of its simulation products and related services, with key buyers including healthcare providers and medical device manufacturers. The company operates globally, serving clients across multiple healthcare segments that require advanced training tools for minimally invasive procedures. Mentice AB's business model focuses on delivering scientifically validated simulation tools that address skill development needs in complex medical procedures. The firm's product offerings cater to both healthcare institutions seeking to train staff and medical device companies requiring validation tools for their products. By specializing in endovascular therapy simulations, Mentice AB serves a niche market with high demand for precise procedural training solutions. The company's global presence allows it to reach clients in various regions seeking advanced medical simulation technology. The company's revenue streams come from the sale of simulation software and hardware systems alongside ongoing service contracts. Healthcare providers purchase these solutions to improve staff competency in endovascular procedures, while medical device manufacturers use them to validate device performance in simulated environments. Mentice AB's solutions are specifically developed for the medical device industry and healthcare providers, creating a dual revenue stream from both sectors. The firm's focus on scientifically validated tools ensures strong market positioning within specialized medical training segments. Mentice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mentice stock

Equity Ratio of Mentice is 44.35 % in 2025.

Equity Ratio of Mentice changed from 44.35 % to 44.35 %, representing a -0.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Mentice since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Mentice with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Mentice

All Key Metrics — Mentice